BioStratum Overview
- Founded
-
1994
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
BioStratum General Information
Description
Developer of proprietary therapeutics designed to focus on scientific advances in basal lamina and related technologies. The company's proprietary therapeutics develop drug candidates that are directed against novel basal lamina extracellular targets involved in degenerative and invasive disease processes fundamental to diabetes, cancer and kidney disease, enabling patients to get help in wound repair and tissue regeneration.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 4825 Creekstone Drive
- Durham, NC 27703
- United States
BioStratum Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Out of Business | 01-Aug-2016 | 000.00 | Completed | Out of Business | ||
| 7. Later Stage VC | 07-Nov-2011 | 00000 | 000.00 | Completed | Generating Revenue | |
| 6. Convertible Debt | 14-Jan-2005 | 000 | 000.00 | Completed | Generating Revenue | |
| 5. Convertible Debt | 22-Aug-2003 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC | 29-Apr-2002 | 0000 | 0000 | Completed | Generating Revenue | |
| 3. Later Stage VC | 27-Mar-2000 | 0000 | 0000 | Completed | Generating Revenue | |
| 2. Grant | 01-Apr-1999 | $16M | $6M | Completed | Startup | |
| 1. Early Stage VC | 01-Apr-1999 | $6M | $6M | Completed | Startup |
BioStratum Patents
BioStratum Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-7381523-B2 | Contacting pancreatic islet cells with somatostatin receptor binding agent; identifying promoters of insulin secretion | Active | 10-May-2004 | 0000000000 | |
| US-20070003986-A1 | Contacting pancreatic islet cells with somatostatin receptor binding agent; identifying promoters of insulin secretion | Active | 10-May-2004 | 0000000000 | |
| US-20100305162-A1 | Methods for the synthesis of pyridoxamine | Active | 09-Feb-2004 | 0000000000 | |
| US-8431712-B2 | Methods for the synthesis of pyridoxamine | Inactive | 09-Feb-2004 | 0000000000 | 00 |
| US-20050272781-A1 | Protecting the hydroxyls of 3-hydroxy-4,5-dimethylol-2-picoline, reacting the 4-methylol group with an imide (especially potasssium phthalimide), cleaving the imide group to deprotect the amine group, and deprotecting the remaining hydroxy groups; post-amadori advanced glycation end-products. | Active | 09-Feb-2004 | C07D213/66 |
BioStratum Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Harry Penner Jr. | Self | Board Member | 000 0000 |
| Paul Marks Ph.D | Self | Board Member | 000 0000 |
| Per Samuelsson | HealthCap | Board Member | 000 0000 |
| Thomas D'Alonzo JD | Self | Board Member | 000 0000 |
| William Freytag Ph.D | Self | Chairman of the Board of Directors | 000 0000 |
BioStratum Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000000 | 07-Apr-2008 | 00000 0000 | 000.00 | Biotechnology | 00000 000 |
| BioCrine | 29-Apr-2002 | Merger/Acquisition | Drug Discovery |
BioStratum Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000000 | Drug Discovery | Solna, Sweden |
BioStratum Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000000 | 07-Apr-2008 | 00000 00000 00 | 000.00 | Completed |
|